JP2014034576A5 - - Google Patents

Download PDF

Info

Publication number
JP2014034576A5
JP2014034576A5 JP2013194611A JP2013194611A JP2014034576A5 JP 2014034576 A5 JP2014034576 A5 JP 2014034576A5 JP 2013194611 A JP2013194611 A JP 2013194611A JP 2013194611 A JP2013194611 A JP 2013194611A JP 2014034576 A5 JP2014034576 A5 JP 2014034576A5
Authority
JP
Japan
Prior art keywords
chemotherapeutic agent
medicament according
treatment
optionally substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013194611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014034576A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014034576A publication Critical patent/JP2014034576A/ja
Publication of JP2014034576A5 publication Critical patent/JP2014034576A5/ja
Pending legal-status Critical Current

Links

JP2013194611A 2007-04-10 2013-09-19 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法 Pending JP2014034576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
US60/922,899 2007-04-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010503045A Division JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014059561A Division JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Publications (2)

Publication Number Publication Date
JP2014034576A JP2014034576A (ja) 2014-02-24
JP2014034576A5 true JP2014034576A5 (enExample) 2014-07-17

Family

ID=39627802

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010503045A Pending JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2013194611A Pending JP2014034576A (ja) 2007-04-10 2013-09-19 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010503045A Pending JP2010523670A (ja) 2007-04-10 2008-04-09 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法

Country Status (31)

Country Link
US (1) US8513266B2 (enExample)
EP (1) EP2139484B9 (enExample)
JP (3) JP2010523670A (enExample)
KR (1) KR101626435B1 (enExample)
CN (2) CN101715345A (enExample)
AU (1) AU2008236562B2 (enExample)
BR (1) BRPI0810206A2 (enExample)
CA (1) CA2683641C (enExample)
CO (1) CO6251254A2 (enExample)
CR (1) CR11100A (enExample)
DK (1) DK2139484T3 (enExample)
DO (1) DOP2009000243A (enExample)
EA (1) EA020022B1 (enExample)
EC (1) ECSP099724A (enExample)
ES (1) ES2430614T3 (enExample)
HN (1) HN2009003002A (enExample)
HR (1) HRP20130688T1 (enExample)
IL (1) IL201284A (enExample)
MA (1) MA31358B1 (enExample)
ME (1) ME00936B (enExample)
MX (1) MX2009010930A (enExample)
MY (1) MY150697A (enExample)
NZ (1) NZ580110A (enExample)
PL (1) PL2139484T3 (enExample)
PT (1) PT2139484E (enExample)
RS (1) RS52939B (enExample)
SI (1) SI2139484T1 (enExample)
TN (1) TN2009000400A1 (enExample)
UA (1) UA100979C2 (enExample)
WO (1) WO2008124161A1 (enExample)
ZA (1) ZA200906764B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
GEP20115304B (en) * 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
JP2010523670A (ja) 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
US8481001B2 (en) * 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
WO2010022128A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012158960A2 (en) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
RU2014107713A (ru) * 2011-07-28 2015-09-10 Дженентек, Инк Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
SG11201401961UA (en) 2011-11-01 2014-05-29 Exelixis Inc N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013071264A1 (en) * 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2860051A1 (en) 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
JP6342396B2 (ja) 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
GEP20217234B (en) * 2016-08-15 2021-03-25 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
FI3769765T3 (fi) 2018-03-19 2024-05-15 Taiho Pharmaceutical Co Ltd Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
US12509456B2 (en) 2019-03-11 2025-12-30 Deciphera Pharmaceuticals, Llc Solid state forms of ripretinib
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
BR112022011372A2 (pt) 2019-12-10 2022-08-23 Univ Indiana Trustees Inibidores de interação de proteína a de replicação (rpa)-dna
ES2991414T3 (es) 2019-12-30 2024-12-03 Deciphera Pharmaceuticals Llc Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CA3238551A1 (en) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
ES2400339T3 (es) * 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
CA2563669A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
TW200710406A (en) * 2005-07-06 2007-03-16 Sbc Corp Leakage current detection apparatus and leakage current detection method
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
GEP20115304B (en) 2005-10-07 2011-10-10 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
MY146420A (en) * 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
JP2010523670A (ja) 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
CA2683820A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US20100150827A1 (en) 2007-04-11 2010-06-17 Exelixis, Inc Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US8481001B2 (en) 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor

Similar Documents

Publication Publication Date Title
JP2014034576A5 (enExample)
AR074575A1 (es) Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer
JP2019501204A5 (enExample)
JP2010523669A5 (enExample)
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2014518544A5 (enExample)
JP2018504418A5 (enExample)
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
JP2010523670A5 (enExample)
JP2016503414A5 (enExample)
RU2013148732A (ru) Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
EA201690608A1 (ru) Способы лечения раковых заболеваний
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CO6251254A2 (es) Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer
MX2020006042A (es) Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
JP2015512398A5 (enExample)
RU2012139825A (ru) Антагонисты неурегулина и применение их в лечении злокачественного новообразования
RU2015143437A (ru) Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
RU2013150102A (ru) Ингибиторы parp для лечения cipn
JP2013523843A5 (enExample)
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2013520431A5 (enExample)